Vytrus BiotechFRA:V5P +3.59%63 PB Ratio is 12.62 as of Jul. 11, 2026, which is 184% above its 10-year median of 4.44. GuruFocus rates FRA:V5P with a GF Score™ of 63/100 and a GF Value™ of €6.81 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,227 Biotechnology companies, Vytrus Biotech ranks worse than 88.92% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-11), Vytrus Biotech's share price is €17.30. Vytrus Biotech's Book Value per Share for the quarter that ended in Dec. 2025 was €1.37. Hence, Vytrus Biotech's PB Ratio of today is 12.62.
The historical rank and industry rank for Vytrus Biotech's PB Ratio or its related term are showing as below:
FRA:V5P'
s PB Ratio Range Over the Past 10 Years
Min: 2.23 Med: 4.44 Max: 14.44
Current: 11.87
During the past 8 years, Vytrus Biotech's highest PB Ratio was 14.44. The lowest was 2.23. And the median was 4.44.
FRA:V5P's PB Ratio is ranked worse than 88.92% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs FRA:V5P: 11.87
During the past 12 months, Vytrus Biotech's average Book Value Per Share Growth Rate was 41.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 25.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 20.60% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Vytrus Biotech was 25.50% per year. The lowest was 12.80% per year. And the median was 17.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vytrus Biotech PB Ratio Related Terms
Vytrus Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vytrus Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vytrus Biotech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vytrus Biotech (FRA:V5P) has a PB Ratio of 12.62 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vytrus Biotech and its competitors. This is 184% above median its historical median of 4.44. Over the past decade, Vytrus Biotech's PB Ratio has ranged from 2.23 to 14.44. According to the industry distribution chart, Vytrus Biotech ranks #1091 out of 1227 companies in the Biotechnology industry, placing it in the top 88.9%.
Is Vytrus Biotech's PB Ratio too high?
Vytrus Biotech's current PB Ratio of 12.62 is 184% above median its 10-year median of 4.44. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 14.44. The Biotechnology industry median PB Ratio is 2.95. Vytrus Biotech's value of 12.62 is 327.8% above this industry median. Based on the distribution chart, Vytrus Biotech ranks #1091 out of 1227 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vytrus Biotech has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #1091 out of 1227 companies for PB Ratio. This places Vytrus Biotech in the lower half of its industry. The industry median PB Ratio is 2.95. Vytrus Biotech's value of 12.62 is 327.8% above this benchmark. Historically, Vytrus Biotech's own PB Ratio has ranged from 2.23 to 14.44 over the past decade. While the company's 10-year median is 4.44 vs. the industry median of 2.95, Vytrus Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current PB Ratio of 12.62 is 327.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vytrus Biotech and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current PB Ratio is 12.62, which is 184% above median its own 10-year median of 4.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (FRA:V5P) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.81, compared to a current price of €17.30 — trading 154% above its estimated fair value. The current PB Ratio is 12.62, which is 184% above median its 10-year median of 4.44 and 327.8% above the Biotechnology industry median of 2.95. Vytrus Biotech's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vytrus Biotech (FRA:V5P), the current PB Ratio is 12.62 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (FRA:V5P) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €17.30 is trading 154% above its estimated GF Value™ of €6.81.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for FRA:V5P:
PB Ratio: 12.62 (184% above median its 10-year median of 4.44)
GF Value™: €6.81 vs. price of €17.30 (154% above fair value)
Industry Position: 327.8% above the Biotechnology median (#1091 of 1227)
No single metric tells the full story. See the FRA:V5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
63GF Score
Get the complete analysis for FRA:V5P
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:V5P has been successfully added to your 
